Palmitoyl Pentapeptide-4
Evidence: B-/C+ — Meaningful Human EvidenceDermatology / Cosmetic Research
Evidence Snapshot
What this grade covers
B-/C+ reflects human topical cosmetic evidence on photoaged facial skin and wrinkles; systemic/injectable evidence remains grade E (not established).
Regulatory Context
Marketed as a cosmetic topical ingredient (not a drug); not FDA-approved or evaluated for any systemic/injectable indication.
Research Takeaway
"Matrixyl" is a commercial/brand family name; it is not automatically identical to palmitoyl pentapeptide-4 in every product sold under that name.
See all 2 evidence claims →Quick Summary
Palmitoyl Pentapeptide-4 -- commercially known under the Matrixyl family of trade names, historically also called palmitoyl pentapeptide-3 in some literature -- has human topical cosmetic research support for photoaged skin and wrinkles, including a 2005 study on photoaged facial skin (PMID 18492182) and a 2023 double-blind randomized trial on crow's-feet wrinkles (PMID 36909866, alongside acetylhexapeptide-3). This evidence is specific to topical application; route and formulation are integral to it, and it cannot support injectable or systemic anti-aging, systemic collagen-increase, muscle-growth, or other systemic regenerative claims. Multi-active cosmetic formulations tested alongside other ingredients cannot have their effects attributed solely to this peptide unless a study specifically isolates it. "Matrixyl" is a commercial/brand family name and is not automatically identical to palmitoyl pentapeptide-4 in every product sold under that name; this page treats palmitoyl pentapeptide-4 as the specific molecule its cited evidence supports.
Mechanism & Research Overview
Palmitoyl Pentapeptide-4 -- commercially known under the Matrixyl family of trade names, historically also called palmitoyl pentapeptide-3 in some literature -- has human topical cosmetic research support for photoaged skin and wrinkles, including a 2005 study on photoaged facial skin (PMID 18492182) and a 2023 double-blind randomized trial on crow's-feet wrinkles (PMID 36909866, alongside acetylhexapeptide-3). This evidence is specific to topical application; route and formulation are integral to it, and it cannot support injectable or systemic anti-aging, systemic collagen-increase, muscle-growth, or other systemic regenerative claims. Multi-active cosmetic formulations tested alongside other ingredients cannot have their effects attributed solely to this peptide unless a study specifically isolates it. "Matrixyl" is a commercial/brand family name and is not automatically identical to palmitoyl pentapeptide-4 in every product sold under that name; this page treats palmitoyl pentapeptide-4 as the specific molecule its cited evidence supports.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
"Matrixyl" is a commercial/brand family name; it is not automatically identical to palmitoyl pentapeptide-4 in every product sold under that name.
Supported
Human topical cosmetic studies support improvement in photoaged skin and wrinkles from topically applied palmitoyl pentapeptide-4; this route/formulation-specific evidence cannot support injectable or systemic anti-aging, systemic collagen-increase, or muscle-growth claims.
Does not establish
Evidence boundary: Topical cosmetic evidence does not establish systemic or injectable efficacy.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Research Areas Being Studied
Research areas discussed on this page reflect the Dermatology / Cosmetic Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Palmitoyl Pentapeptide-4
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.